Acute Otitis Externa Clinical Trial
Official title:
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
The purpose of this study was to demonstrate the superiority of AL-60371, 0.3% Otic Suspension relative to AL-60371 Vehicle based on clinical cures at test-of-cure (TOC) for the treatment of acute otitis externa (AOE).
Status | Completed |
Enrollment | 768 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months and older |
Eligibility |
Inclusion Criteria: - At least 6 months of age. - Clinical diagnosis of acute otitis externa (AOE) based on clinical observation and of presumed bacterial origin in at least one ear. - Combined numerical score of =4 in at least one affected ear at the Day 1 exam for tenderness, erythema, and edema. - Agree to refrain from water immersion of the ears during the conduct of the entire study. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Duration of signs or symptoms of AOE greater than 28 days in the affected ear(s) as reported by patient or parent/guardian. - Presence of a tympanostomy tube or perforated tympanic membrane in the affected ear(s). - Clinically diagnosed otic disease other than AOE (eg, malignant otitis externa) in the affected ear(s). - Known or suspected ear infection of yeast, fungal or mycobacterial origin in the affected ear(s). - Prior otologic surgery within 6 months of study entry in the affected ear(s). - Known or suspected allergy or hypersensitivity to quinolones or other ingredients present in the medications to be used in the study. - Patients who use ear plugs, head phones or ear buds and are unwilling to discontinue their use during the study period. - Other protocol-defined exclusion criteria may apply. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Alcon Research |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit | An otoscopic exam was conducted by the physician. Clinical cure was considered attained if the sum of the numerical scores of the 3 signs and symptoms of AOE (tenderness, erythema, and edema) was 0 at Day 11. In this analysis, the clinical cure outcome at Day 11 (TOC) was considered a failure for all pathogen positive patients who did not complete the study (for any reason). Proportion of patients is reported as a percentage. | Day 11 | No |
Secondary | Proportion of Patients With Microbiological Successes at the Day 11 (TOC) Visit | Microbiological success was considered attained if all pretherapy bacteria were absent from the exit otic specimen. The presence of fungi and/or yeast was not considered in the determination of microbiological success. In this analysis, the microbiological success value at Day 11 (TOC) was considered a failure for all pathogen positive patients who did not complete the study (for any reason). Proportion of patients is reported as a percentage. | Day 11 | No |
Secondary | Median Time to Cessation of Ear Pain as Reported by the Patient or Parent/Legal Guardian Via the Telephone Diary | Cessation of ear pain was defined as occurring on the first time point that ear pain was absent (morning or evening) and did not return in any subsequent diary entries. Day 1 was the starting point for this time-to-event analysis. For this analysis, all patients who did not complete the study and ear pain never ceased had their ear pain considered as being present throughout the planned duration of the study. | Time to event, up to Day 11 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02918773 -
Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)
|
N/A | |
Not yet recruiting |
NCT04636957 -
A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)
|
Phase 3 | |
Completed |
NCT01447017 -
A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis
|
Phase 2 | |
Completed |
NCT02801370 -
Phase 3 Study of OTO-201 in Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT00750633 -
A Phase III Study of an Otic Formulation in Acute Otitis Externa
|
Phase 3 | |
Terminated |
NCT00945802 -
FST-201 In The Treatment of Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT03196973 -
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa
|
Phase 3 | |
Recruiting |
NCT01584271 -
Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)
|
Phase 2 | |
Completed |
NCT02216071 -
Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT00961675 -
FST-201 in the Treatment of Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT01535560 -
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
|
Phase 3 |